Form 4: Amicus Therapeutics Acquired by BioMarin for $14.50/Share

Director Eiry Roberts reports the disposal of all Amicus Therapeutics equity holdings following the company's acquisition by BioMarin Pharmaceutical Inc.

Summary

• Director Eiry Roberts disposed of 76,275 shares of Amicus Therapeutics common stock at a price of $14.50 per share.
• Multiple tranches of stock options totaling 233,861 shares were cancelled and converted into cash payments based on the $14.50 acquisition price.
• The transactions were executed on April 27, 2026, in connection with the completed merger with BioMarin Pharmaceutical Inc.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing documenting the final exit of a director following a completed corporate acquisition.

Positives

• Full vesting of restricted stock units and stock options occurred upon the consummation of the merger.
• Shareholders and directors received a defined cash exit price of $14.50 per share.

Negatives

• The reporting person no longer holds any equity interest in Amicus Therapeutics following the acquisition.

Risks

• No ongoing risks as the issuer has been acquired and the reporting person has exited their position.

Future Outlook

The company has been acquired by BioMarin Pharmaceutical Inc.; therefore, no further forward-looking guidance is provided by the reporting person.

Industry Context

StockSavvy.ai notes that this filing confirms the finalization of a significant M&A event in the biotechnology sector, reflecting ongoing consolidation trends where larger pharmaceutical entities acquire specialized rare disease drug developers.

Comparison to Industry Standards

• The acquisition price of $14.50 represents the final valuation for the entity, consistent with standard cash-out merger structures in the biotech industry.

Stakeholder Impact

• Shareholders have had their equity converted to cash at the merger price of $14.50 per share.

Next Steps

• None; the reporting person has zeroed out their holdings due to the acquisition.

Key Dates

Keywords

Amicus Therapeutics, BioMarin, Merger, Acquisition, Form 4, Insider Transaction, FOLD